project id: TCGA-UCEC; case submitter id: TCGA-AX-A3G4; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.3; rna integrity number: 8.3; age at index: 60; days to birth: -22099; ethnicity: not hispanic or latino; gender: female; race: native hawaiian or other pacific islander; vital status: Alive; year of birth: 1950; age at diagnosis: 22099; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 9.0; figo stage: Stage IIIC; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 463; initial weight: 130.0; oct embedded: false; preservation method: Unknown; sample id: bb0d2369-9133-4189-a386-25feaa78c6e9; sample submitter id: TCGA-AX-A3G4-01A; portion id: c75328a8-3829-4468-a282-502a37d68331; portion submitter id: TCGA-AX-A3G4-01A-11; slide id: db36c5ff-d254-406d-8d8e-4f73817ce863; slide submitter id: TCGA-AX-A3G4-01A-01-TS1; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 4.0; percent neutrophil infiltration: 1.0; percent normal cells: 3.0; percent stromal cells: 3.0; percent tumor cells: 90.0; percent tumor nuclei: 94.0; section location: TOP;